Previous Article | Next Article 
Journal of Virology, January 2001, p. 161-170, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.161-170.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Duck Hepatitis B Virus Expresses a Regulatory
HBx-Like Protein from a Hidden Open Reading Frame
Shau-Feng
Chang,1,2
Hans Jürgen
Netter,1,3
Eberhard
Hildt,4
Ralph
Schuster,5
Stephan
Schaefer,5
Yin-Chen
Hsu,2
Andreas
Rang,1 and
Hans
Will1,*
Heinrich-Pette-Institut für
experimentelle Virologie und Immunologie an der Universität
Hamburg, Hamburg,1 Institut
für experimentelle Onkologie und Therapieforschung, Klinikum
rechts der Isar, Munich,4 and
Institut für Medizinische Virologie,
Justus-Liebig-Universität, Giessen,5
Germany; Molecular Biomedical Technology Division,
Biomedical Engineering Center, Industrial Technology Research
Institute, Hsinchu, Taiwan2; and Sir
Albert Sakzewski Virus Research Centre, Brisbane,
Australia3
Received 31 March 2000/Accepted 2 October 2000
 |
ABSTRACT |
Duck hepatitis B viruses (DHBV), unlike mammalian hepadnaviruses,
are thought to lack X genes, which encode transcription-regulatory proteins believed to contribute to the development of hepatocellular carcinoma. A lack of association of chronic DHBV infection with hepatocellular carcinoma development supports this belief. Here, we
demonstrate that DHBV genomes have a hidden open reading frame from
which a transcription-regulatory protein, designated DHBx, is expressed
both in vitro and in vivo. We show that DHBx enhances neither viral
protein expression, intracellular DNA synthesis, nor virion production
when assayed in the full-length genome context in LMH cells. However,
similar to mammalian hepadnavirus X proteins, DHBx activates cellular
and viral promoters via the Raf-mitogen-activated protein kinase
signaling pathway and localizes primarily in the cytoplasm. The
functional similarities as well as the weak sequence homologies of DHBx
and the X proteins of mammalian hepadnaviruses strongly suggest a
common ancestry of ortho- and avihepadnavirus X genes. In addition, our
data disclose similar intracellular localization and transcription
regulatory functions of the corresponding proteins, raise new questions
as to their presumed role in hepatocarcinogenesis, and imply unique
opportunities for deciphering of their still-enigmatic in vivo functions.
 |
INTRODUCTION |
Since the identification of
hepatitis B virus (HBV) in humans, several related viruses have been
isolated from mammalian and avian species (9, 53, 68).
These viruses, known as hepadnaviruses, display high liver tropism,
have a narrow host range, and cause acute and chronic hepatitis.
Chronic infection with mammalian hepadnaviruses (orthohepadnaviruses)
is associated with the development of liver cancer.
The hepadnaviruses are small enveloped DNA viruses with a unique virion
ultrastructure. The viral genome is a partially duplexed, relaxed
circular DNA molecule (rcDNA) with a size of about 3 kb which upon
entry of the cell is converted into a covalently closed circular
episome. This covalently closed circular DNA is then transcribed by the
host RNA polymerase II, synthesizing subgenomic mRNAs and a
greater-than-genome-length RNA known as pregenomic RNA or C-mRNA.
Distinctive for all hepadnaviruses is the method of replication by
reverse transcription of the pregenomic RNA into rcDNA. Transcripts
encoding the envelope proteins, the nucleocapsid protein, the
polymerase protein (P protein), and, as exclusively described so far in
orthohepadnaviruses, the X protein have been identified. The
organization of the viral genome is very compact, with overlapping
reading frames and promoters and enhancer elements located within
coding regions (20).
The X proteins of orthohepadnaviruses affect signal transduction
pathways, transcription, cell transformation, and proliferation (1, 8, 46, 70). The HBV-specific X protein (HBx) is expressed in vivo, as shown by immunohistology and indirectly by
identification of an HBx-specific immune response in infected individuals (64). In vivo expression of the X protein
(WHx) has been demonstrated most convincingly for woodchuck hepatitis B
virus (WHV)-infected animals (14, 32). HBx and WHx are
predominantly localized in the cytoplasm, but a small fraction has also
been found in the nucleus and associated with the nuclear framework (13, 15, 26, 49, 54, 69). HBx transactivates a wide range
of cellular and viral promoters (1, 8, 46, 70). It acts,
for instance, as a cytoplasmic activator of known mitogenic signal
transduction pathways, in particular the Ras-Raf mitogen-activated protein (MAP) kinase cascade (2, 4, 15, 34, 47, 67). Thus,
it can activate a variety of transcription factors and modulate cellular gene expression. HBx also activates transcription directly through protein-protein interactions (11, 26, 27, 44, 50,
51). Further interactions with components of the proteasome (19, 30, 31, 57), a DNA repair protein (33,
40), and a cellular factor with an inhibitory effect on the
transactivation properties of HBx (45) have been
characterized which offer explanations for the pleiotropic effects of HBx.
In vivo experiments have shown that WHx is required for the
establishment of chronic infection (10, 72), but HBx is
not essential for replication in hepatoma cells (6). Since
HBx has these multiple effects on regulatory cellular pathways, it has
been speculated that it might be involved in the development of
hepatocellular carcinoma (1, 8, 46, 70). HBx-mediated oncogenic transformation of immortalized rodent cells (29, 59, 61) and development of hepatocellular carcinoma in some strains of transgenic mice (35, 62, 71) support this speculation. The p53-dependent and -independent pro- and antiapoptotic, as well as
cell cycle-regulatory, effects of HBx may also contribute to
hepatocarcinogenesis (3, 5, 12, 17, 35, 60, 65-67). Despite the many studies of functions of mammalian X proteins, there
are so far no data as to the precise structure of X-specific mRNA in
infected cells from which this protein is translated (70). Infection of Pekin ducks with duck hepatitis B virus (DHBV) is the most
convenient and useful animal model for studies of the life cycle of
hepadnaviruses but is less suitable for studies of
hepadnavirus-mediated hepatocarcinogenesis because chronic infection of
ducks with DHBV does not appear to be associated with the development
of liver cancer (16). This is believed to be due to the
absence of an X gene in all known DHBV isolates. Although
X-protein-like sequences were proposed to be present in the middle of
the DHBV nucleocapsid protein (DHBc) (18), functional
similarities of DHBc with the mammalian hepadnavirus X proteins have
never been identified. Moreover, the existence of an open reading frame
(ORF) in the hepadnavirus genomes isolated from grey herons
(48), snow geese (9), a Ross goose
(48), and white storks (H. J. Netter, S.-F. Chang,
and H. Will, unpublished observation) in a position similar to that of
the X gene of orthohepadnaviruses argues that an X-like protein may be
expressed from avian hepadnavirus genomes.
These findings prompted us to investigate whether avian
hepadnaviruses also express an HBx-like regulatory protein. Here, we
demonstrate that such a protein is indeed encoded by a hidden DHBV ORF
located at a position analogous to those of the X genes of mammalian
hepadnaviruses. Furthermore, we show that this protein is expressed in
vitro and in vivo and has functions similar to those of the X proteins
of mammalian hepadnaviruses.
 |
MATERIALS AND METHODS |
Plasmids.
A head-to-tail dimer of the DHBV3 isolate
genome was inserted via EcoRI into the vector pUC18, which
resulted in plasmid pDHBV3. To prevent the expression of X-like
proteins, an analogous plasmid (pDHBV3-X-K.O.) that contains a stop
codon in each of the two X-like ORFs of the tandemerized DHBV3 genomes
was produced as follows. By oligonucleotide-directed mutagenesis, a
G-to-A nucleotide change which converts the codon for tryptophan (TGG)
at amino acid position 28 in the X-like ORF into a stop codon (TAG) was introduced at position 2371. To achieve this, DHBV3 DNA was amplified with the primers DHBV2144(+) and DHBV2371GA(
) and, in a separate reaction, with the primers DHBV257(
) and DHBV2371GA(+). The mixture of both amplified products was used as a template in a second PCR
performed with the primers DHBV2144(+) and DHBV257(
). The product of
this PCR was digested with NcoI and EcoRI, and
then the 0.67-kb fragment which contained the mutation was purified. The corresponding wild-type fragment was replaced with the purified PCR
fragment, and then the mutated monomeric DHBV genome was head-to-tail dimerized.
Several plasmids for expression of DHBx under the control of the
cytomegalovirus (CMV) promoter were constructed by inserting the
following XbaI/HindIII PCR fragments into
vector pRK5 linearized by the same restriction enzymes. Primers
DHBV3-His-M1X and DHBV-X-stop were used to amplify from DHBV3 DNA a
fragment coding for a fusion protein which begins with six histidines,
followed by a methionine and then the complete DHBx sequence (plasmid
pDHBV3-M1X). For the construction of plasmid pDHBV3-M28X, the primers
DHBV3-His-M28X and DHBV-X-stop were used to amplify a similar DNA
fragment which encodes the same fusion protein except for the first 27 amino acids of DHBx. Plasmid pDHBV3-M28X-stop is almost identical to pDHBV3-M1X but has a stop codon instead of a tryptophan codon at
position 28 of DHBx. The corresponding PCR fragment was obtained by
using pDHBV3-X-K.O. as a template and primers DHBV3-His-M1X and
DHBV3-X-stop.
Constructs used for the analysis of C-gene promoter activity were
obtained by amplification of the core promoter regions (nucleotides
1658 to 2520) using pDHBV3 or pDHBV3-X-K.O as a template and the
primers DHBV1557(+) and DHBV2520-HindIII. The PCR products were
digested with
BamHI and
HindIII and then
cloned into
BglII and
HindIII sites of the
pGL3 basic vector (Promega, Madison, Wis.).
This resulted in plasmids
pGL3-wt and pGL3-X-K.O. The expression
plasmid for the HBV X protein
was reported previously (
56).
Cell lines and transfection procedures.
The chicken
hepatoma-derived LMH cells were maintained in Dulbecco's modified
Eagle's medium-F12 medium (Gibco/BRL). Human hepatoma cells (HepG2 and
HuH-7), human embryonal kidney cells (293), and African green monkey
kidney cells (Cos7) were grown in Dulbecco's modified Eagle's medium.
The cell lines were transfected with the help of the FuGene6 reagent;
by lipofection, using DOTAP (Roche Molecular Biochemicals, Pentzberg,
Germany) according to the manufacturer's instructions; or by calcium
phosphate precipitation.
Luciferase, chloramphenicol acetyltransferase (CAT), and
-galactosidase assays.
The transfected cells (HepG2 and LMH)
were harvested at day 2 after transfection and lysed in Tris buffer
(250 mM; pH 7.8) by five cycles of thawing and freezing. The protein
concentration of the lysate was determined by the Bradford assay.
Twenty micrograms of protein was used for the luciferase activity assay
(Roche Molecular Biochemicals) according to the manufacturer's
recommendations. A plasmid expressing
-galactosidase was
cotransfected, and the level of expression of this enzyme was used as
an internal standard. All assays were done in duplicate, and all
experiments were repeated at least once by performing two or more
independent transfections.
For the CAT assay, 8 × 10
5 HepG2 or 293 cells were
transfected with the reporter construct pSV2-CAT, p3xAP-1-CAT, or
p2xNF-

B-CAT
and with the large HBV envelope protein expression
plasmid pSVLM-S
or the different plasmids expressing HBx or the DHBV
X-like proteins.
To inhibit the activity of c-Raf-1 kinase, 2.5 µg of
the plasmid
expressing the transdominant-negative mutant HCR13.1
(
36) or
pErk2tdn (kindly provided by W. Fantl, San
Francisco, Calif.)
was used for transfection. Transfection efficiencies
were standardized
by cotransfection of a luciferase reporter
plasmid containing
the luciferase gene under the control of the
nonstimulatable minimal
promoter of pTK-luciferase. The CAT activity
was determined by
using a commercial enzyme-linked immunosorbent assay
system, and
the luciferase activity was determined as described
above.
Antibodies raised against peptides specific for DHBx.
The
sequences of peptides X2 (ILLTAHPGTNRLIGR) and X3 (GYVELKNYTPLLRSC)
correspond to DHBx amino acids 46 to 60 and 76 to 90 derived from the
DHBV1 genome, respectively. The sequence of peptide p759
(AVVPCDCTFGMYHCL) is identical to the C-terminal end of the predicted
X-like protein of HHBV4 (48) and almost identical to the
corresponding region of DHBx proteins. All three peptides were
conjugated to keyhole limpet hemocyanin and then injected into rabbits
(subcutaneously and intramuscularly) to raise the
-X2,
-X3, and
-p759 antibodies. A recombinant protein containing the complete DHBx
sequence predicted from the ORF was expressed in Escherichia
coli by using the expression vector pQE9 (Qiagen,
Düsseldorf, Germany), which places a six-histidine tail at the
protein's N terminus. To construct this recombinant plasmid, a DNA
fragment encoding DHBx was generated by PCR using the primers DHBV3-2289X and DHBV3-X-stop. This fragment was then digested with
BamHI and HindIII and cloned into the vector
linearized by the same restriction enzymes. The recombinant protein was
purified according to the procedure provided by the plasmid
manufacturer and then injected into two rabbits. The resulting antisera
(
-DHBV3X) were used as a mixture for immunoblotting.
Indirect immunofluorescence staining.
The Cos7 cells were
grown on coverslips and transfected with plasmids expressing the
DHBV3-M1X, DHBV3-M28X, and HBx proteins with N-terminal tags of six
histidines under the control of the CMV promoter. The cells were fixed
in methanol for 5 min at
20°C, and then incubated for 30 s in
acetone. The fixed cells were incubated for 1 h at room
temperature with an
-six-His monoclonal antibody (Clontech, Palo
Alto, Calif.) diluted 1:5,000 in phosphate-buffered saline (PBS). For
detection, a fluorescein isothiocyanate (FITC)-conjugated
-mouse
immunoglobulin antibody (Dianova, Hamburg, Germany), diluted 1:200 in
PBS, was applied.
Immunoblotting.
The cells were rinsed with PBS and
then directly lysed in sodium dodecyl sulfate (SDS) loading buffer. The
samples were boiled, separated by SDS-polyacrylamide gel
electrophoresis, and transfered to a nitrocellulose membrane or a
polyvinylidene difluoride membrane. The blots were incubated with
rabbit antiserum raised against DHBV-X peptides (
-X2,
-X3, or
-p759) or a mouse antiserum specific for the six-histidine tag
(Clontech). This procedure was repeated three to four times to increase
the sensitivity of detection. The proteins were then visualized after
being incubated with an appropriate peroxidase-coupled secondary
antibody followed by incubation with a chemiluminescence substrate.
DNA and protein sequence analyses.
Sequence analysis was
performed with the software provided by MacVector (Oxford Molecular
Group, Oxford, United Kingdom) and with the package provided by the
Wisconsin Genetics Computer Group. The X-protein sequences of all
hepadnaviruses used for alignment were taken from GenBank (National
Center for Biotechnology Information, Bethesda, Md.). Accession numbers
were as follows: DHBV1, X58567; DHBV3 (see reference
63); DHBV26, X58569; snow goose hepatitis B virus 15 (SGHBV15), AF110997; Ross goose hepatitis B virus (RGHV), M95589;
heron hepatitis B virus type 4 (HHBV-4), M22056; HBV, J02203; ground
squirrel hepatitis virus, K02715; and WHV, M11082.
Synthetic oligonucleotides.
The following oligonucleotides
were used: DHBV3-His-M1X;
5'-GCTCTAGATGCATCACCATCACCATCACCATCACTTAAACCTCGATGCCTC-3';
DHBV3-His-M28X, 5'-GCTCTAGATGCATCACCATCACCATCACCATCACTGGCCAAACAGTTGCTC-3';
DHBV3-X-stop, 5'-TCATAAACGATGGTACATACC-3';
DHBV-2371GA(+), 5'-GCTGTGTTAGCCAAACAG-3'; DHBV-2371GA(
), 5'-CTGTTTGGCTAACACAGC-3';
DHBV2520-HindIII, 5'-CCAAGCTTAGCCTGTGTGGAATATATATTGC-3'; DHBV1557(+), 5'-GGCTTGCTGTATCTGACGG-3'; DHBV257(
),
5'-CCACGAGGTTTTCTAGTACC-3'; DHBV2144(+),
5'-CCTTTGCCACGTGTAGC-3'; and DHBV3-2289X,
5'-CGGGATCCATGTTAAACCTCGATGCCTC-3'.
 |
RESULTS |
Identification and characterization of the
DHBV-specific X-like ORF.
The genomes of all known
avihepadnaviruses, except those of DHBV, contain an ORF in a position
analogous to that of the X gene of mammalian viruses. It was previously
speculated but not experimentally proven that a protein with functions
similar to those of mammalian hepadnavirus X protein may be expressed
from these ORFs (9, 48). We considered it unlikely that
DHBV lacks such an ORF and therefore investigated whether DHBV genomes
have X-like ORFs without a conventional translation initiation codon from which an X-like protein could be synthesized. Inspection of the
sequences of all DHBV genomes deposited in the GenBank database
revealed such an ORF in a position analogous to those of X and X-like
ORFs known for all other hepadnaviruses. Provided a conventional
translational start codon is used for expression of an X-like protein
of HHBV, RGHV, and SGHBV (Fig. 1A) (note that only a selective set of the known DHBV, SGHBV, and HHBV sequences is shown) and a nonconventional codon at the very amino-terminal end is
used in the case of DHBV (Fig. 1B), the corresponding DHBV X-like
protein could be longer than all other putative avihepadnavirus X-like
proteins.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of putative avihepadnavirus X-like proteins
and potential translation initiation codons for DHBx. (A) Alignment of
predicted X-like protein sequences derived from cloned DHBV1, DHBV3,
DHBV26, SGHBV15, HHBV4, and RGHV genomes. For all DHBV strains missing
the conventional AUG start codon at the beginning of the corresponding
ORFs, the longest possible reading frame is given. Protein sequences
conserved among the different avihepadnaviruses are boxed. Identical
amino acids are indicated by dark shading, and similar amino acids are
indicated by light shading. The conventional translation start codons
(M) in SGHBV, HHBV, and RGHV are underlined. (B) Potential
nonconventional translation initiation codons in the ORF of DHBx are in
boldface and underlined.
|
|
There is over 90% sequence identity among the putative X-like
protein sequences of all DHBV isolates (data not shown). In
addition,
the homology of the deduced X-like protein sequences
among the various
DHBV isolates and the evolutionarily most closely
related SGHBV is more
than 80% (Fig.
1A). In contrast, the homology
between the
corresponding sequences of DHBV isolates and the more
distantly related
HHBV or RGHV ranges only between 40 to 50% (Fig.
1A). In general,
sequence identity and similarity among the various
X-like proteins are
higher in the C-terminal region than at the
amino-terminal end (Fig.
1A). This is in part due to the length
variation of the X-like ORFs.
For instance, all DHBV genomes encode
a putative X-like protein with a
maximum of 114 amino acids, except
the isolates DHBV22 and DHBV26,
which lack the first 7 amino acids
at the very N terminus (Fig.
1A and
data not shown). Moreover,
the X-like ORFs of all other known
avihepadnaviruses have a conventional
AUG translation initiation codon
from which translation of the
protein could be initiated, but it is
located at different positions
for each member of the avihepadnaviruses
(Fig.
1A). HHBV, which
is most distantly related to DHBV, may therefore
express the shortest
X-like protein of all hepadnaviruses. All of the
avian hepadnavirus
X-like proteins deduced from the DNA sequences have
only very
low primary sequence similarity to mammalian X proteins (see
below).
Detection of DHBx expression in chronically infected duck
liver.
In order to determine whether a protein is expressed from
the X-like ORF of DHBV, we produced antibodies against specific synthetic peptides with amino acid sequences from different regions of
the predicted protein (
-X2,
-X3, and
-p759) and against a
recombinant DHBV X protein expressed in E. coli (
-DHBx)
and used them to provide direct evidence for expression of DHBx in vivo. When extracts of livers of chronically infected ducks were analyzed by immunoblotting, three of the four antisera reacted with a
protein of 12.5 kDa. No reactivity at the corresponding position was
observed in the noninfected liver sample (Fig.
2A). Immunoblots of both liver extracts
with polyclonal anti-core and anti-preS antibodies performed as
controls showed expression of core and preS proteins in the infected
liver only (Fig. 2A). Taken together, these data indicate that a
protein is expressed from the X-like ORF of DHBV in the chronically
infected liver.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of DHBV X-like protein in chronically infected
duck liver and in transfected LMH cells by immunoblotting. (A). Protein
extracts from a chronically infected duck liver (lanes 1) and a
noninfected duck liver (lanes 2). The types of antisera used for
blotting are indicated at the bottom, and the DHBV X-like protein-,
core-, and major preS protein-specific signals are marked by
arrowheads. (B). Protein extracts from LMH cells transfected with
pDHBV3 and pDHBV3-X-K.O. DNA or from untransfected LMH cells (mock).
The position of the band specifically reacting with antibody from
-X2 peptide antiserum is indicated.
|
|
A protein is expressed from the DHBV X-like ORF in LMH cells
transfected with full-length DHBV DNA.
Next we tested whether the
protein encoded by the X-like ORF of DHBV is also expressed in vitro.
Chicken hepatoma (LMH) cells were transfected with plasmid pDHBV3,
which contains a dimeric full-length genome of isolate DHBV3, as well
as with plasmid pDHBV3-X-K.O, which contains the corresponding knockout
mutant with a stop codon in the X-like ORF. The expression of the
protein encoded by the DHBV X-like ORF was then analyzed by
immunoblotting with the X-specific peptide antisera and cell extracts
of the transfected cells. In LMH cells transfected with pDHBV3, a weak
but specific band corresponding to a protein with an apparent molecular
mass of approximately 12 kDa was identified (data are shown for
-X2
peptide antiserum [Fig. 2B]). These bands were not observed in
untransfected cells or in cells transfected with the DHBV-X knockout
mutant DNA. These data strongly indicate that a protein, designated
DHBx, is expressed from the X-like ORF of the DHBV3 genome in a cell
culture system and that is identical in size to that expressed in
chronically infected duck liver.
DHBx affects neither viral protein expression nor viral DNA
synthesis in LMH cells.
In order to investigate whether DHBx
affects the expression of structural proteins of DHBV, we analyzed the
expression of the preS and core proteins in LMH cells after
transfection with plasmids containing the DHBV3 wild-type genome or the
mutated DHBV3 genome, which contains a stop codon within the X ORF.
This was done by immunoblotting the cell extracts using DHBV preS- and
DHBV core protein-specific antisera. Equal loading of the slots with
proteins was controlled by measuring the amount by the Bradford assay
(data not shown). Comparison of the lanes of the blot with extracts
derived from cells transfected with the wild-type and X-K.O. genomes
showed similar levels of preS and core proteins (Fig. 3A and
B). The transfection efficiencies
obtained with the two genomes were very similar, as was evident from
the fact that the same amount of
-galactosidase (variability, less than 10% [data not shown]) was expressed from a cotransfected reporter plasmid. The amounts of intracellular replicative
intermediates and of secreted virions were also very similar for all
viral genomes, as was evident from the corresponding Southern
blots with DNA extracted from the transfected cells and from the
secreted virus particles (Fig. 3C and D). Northern blotting of
poly(A)-containing RNA from cells transfected with both viral genomes
revealed neither a significant difference in the types and amounts of
mRNAs expressed nor an mRNA which might be transcribed from only the
DHBx coding region (Fig. 3E). These data indicate that DHBx expression
affects neither core and preS protein expression nor viral DNA
synthesis and virion secretion in cell culture. In addition, these data suggest that DHBx has no strong modulatory effect, if it has any at
all, on the steady-state levels of viral transcripts and may itself be
translated either from a very minor DHBx-specific mRNA or from any of
the other viral mRNAs.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of the role of DHBx for core and preS protein
expression and viral DNA synthesis. Immunoblots and Southern blots were
obtained from core particles and particles derived from the culture
medium of LMH cells, respectively. The LMH cells were transfected with
pDHBV3 DNA and pDHBV3-X-K.O. DNA, as well as from nontransfected LMH
cells (mock). (A) PreS envelope proteins detected with a polyclonal
-DHBV preS antibody. The positions of the major preS proteins are
marked by arrowheads. (B) Core protein detected with a polyclonal
-DHBV core antibody. (C) Intracellular replication intermediates
from core particles of transfected cells. (D and E) Viral DNAs from
secreted virus particles as well as from poly(A)+ mRNA
isolated from transfected cells were detected by Southern (D) and
Northern (E) blotting, respectively, with labeled HBV probes. (F)
Loading of the Northern blot with equal amounts of cellular RNA was
controlled by hybridization with a GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) probe. RC, rcDNA; L, linear DNA; SS, single-stranded
DNA.
|
|
The knockout mutation introduced into the X-like ORF (stop codon TAG at
positions 2370 to 2372), which is also located in
the core promoter
region (
43,
55), may have affected core
promoter activity,
viral mRNA half-life, and viral protein translation
efficiency without
a notable effect on overall steady-state levels
of viral proteins
compared to the wild-type genome. In order to
examine the possible
effect on core promoter activity, we tested
the core promoter
activities of DNA fragments (nucleotides 1658
to 2520) which
cover the X-like ORF of DHBV3 with and without
the knockout mutation.
These fragments were cloned upstream of
the luciferase reporter gene
into the eukaryotic promoterless
plasmid pGL3 (Fig.
4A). After transfection into LMH and
HuH-7
cells, similar promoter activities were measured when comparing
the wild-type fragment and the X-K.O. mutant-specific fragment
(Fig.
4B
and C). However, the activities of two promoter fragments
were more
than 100-fold higher in LMH cells than in HuH-7 cells.
Taken together,
these results indicate that the core promoter
activity was not altered
by the X-K.O. mutation, confirming our
conclusion that DHBx has no
significant effect on core protein
synthesis.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the core promoter activities of DHBV3
and DHBV3-X-K.O. DNA fragments in transfected cells by luciferase
assay. (A) Schematic diagram of the core promoter fragments. The
nucleotide positions at the 5' and 3' ends of the DHBV-specific
sequence are indicated. The positions of the first nucleotide of the
DHBV X-like ORF and of the mutation leading to a stop codon in
DHBV3-X-K.O. are given, and their locations are marked by an arrow and
an asterisk, respectively. (B and C) Luciferase activity of the tested
constructs in LMH (B) and HuH-7 (C) cells lysed 2 days after
transfection. basic, transfection of the luciferase reporter plasmid
without the core promoter, used as a control. The values are the
averages of two independent transfection experiments performed in
duplicate. The standard deviation was too small to be indicated. wt,
wild type; RLU, relative light units.
|
|
Subcellular localization and electrophoretic mobility of tagged
DHBx proteins.
The low level of DHBx protein expression in
full-length DHBV DNA-transfected cells and DHBV-infected livers
prevented unequivocal subcellular localization of DHBx by indirect
immunofluorescence staining. To circumvent this problem, we expressed
DHBx with N-terminal histidine tags under the control of a strong
foreign promoter (the CMV IE promoter). In these constructs we forced
translation of the tagged DHBx mRNA to initiate at the codon
corresponding to amino acid position 1 or 28 or to stop at the codon of
the DHBV X-like ORF corresponding to amino acid 28 by introducing a
start (AUG) and/or stop codon at the corresponding positions, plasmids pDHBV3-M1X, pDHBV3-M28X, and pDHBV3-M28X-stop,
respectively. This was done because the authentic translation
initiation codon of DHBx is not known and because analysis of the sizes
of these DHBx proteins by immunoblotting may provide hints as to the
location of the DHBx translation initiation codon.
Expression of the tagged DHBx proteins was examined by
immunoblotting 2 days after the transfection of different cell lines
(LMH, Cos7, and 293) with these constructs. When the amino-terminal
X-specific peptide sera

-X2 and

-X3 were used, His-tagged
DHBV-M1X
and -M28X proteins of the expected sizes (ca. 15 and 10 kDa)
were
detected (Fig.
5 and data not
shown). Since the size of the DHBx
expressed under authentic viral
promoter control is 12.5 kDa and
the polyhistidine tag usually
increases the electrophoretic mobility
by only approximately 1 kDa, it
is possible that the nonconventional
translation codon used in vivo is
located between amino acid positions
1 and 28. Unexpectedly,
immunoblotting of proteins from cells
transfected with pDHBV3-M28X-stop
performed with

-X2 resulted
in a specific, albeit weakly stained,
band corresponding to a
protein with an apparent molecular mass of 8 kDa (Fig.
5). This
band may correspond to an amino-terminally truncated
DHBx protein
synthesized by translation initiation at a nonconventional
start
codon downstream of the stop codon at position 28.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 5.
Full-length and truncated versions of DHBx
expressed under the control of the CMV promoter in LMH cells. Protein
extracts from mock-transfected LMH cells (mock) and from LMH cells
transfected with the plasmid pDHBV3-M1X, pDHBV3-M28X, or
pDHBV3-M28X-stop were separated by SDS-polyacrylamide gel
electrophoresis and immunoblotted by using anti-DHBx peptide serum X2
(top) or X3 (bottom). The DHBx-specific bands are marked by
asterisks.
|
|
For subcellular localization of the tagged DHBx proteins by indirect
immunofluorescence staining, transfected Cos7 cells were
examined using
a polyhistidine-specific monoclonal antibody and
a FITC-labeled
anti-mouse antibody. DHBx proteins expressed from
pDHBV3-M1X and -M28X
proteins were detected predominantly in the
cytoplasm (Fig.
6, top), with the most intense staining
close
to the nuclear membrane, a pattern identical to that seen with
HBV-specific histidine-tagged HBx protein (Fig.
6). These results
demonstrate that HBx and DHBx have similar subcellular distributions.

View larger version (99K):
[in this window]
[in a new window]
|
FIG. 6.
Localization of DHBx in transfected cells. Indirect
immunofluorescence staining of Cos7 cells transfected with constructs
expressing His-tagged DHBx (pDHBV3-M1X and pDHBV3-M28X) and HBx. (Top)
Recombinant proteins were detected by a monoclonal -six-His antibody
and a FITC-coupled secondary antibody and visualized by fluorescence
microscopy. (Bottom) Area corresponding to the top row in
phase-contrast microscopy.
|
|
DHBx stimulates promoters of cellular and viral origin via the
Raf-MAP kinase signaling pathway.
Mammalian hepadnavirus HBx
proteins stimulate transcription of a large variety of cellular and
viral genes. To investigate whether DHBx has a similar function, some
of the CMV-DHBx expression plasmids mentioned above (pDHBV3-M1X,
pDHBV3-M28X, and pDHBV3-M28X-stop) were cotransfected into HepG2 and
293 cells with plasmids containing different promoter elements derived
from the AP1 gene, the NF
B gene, and the late promoter of simian
virus 40 cloned upstream of the CAT reporter gene. As a positive
control, a plasmid (pSVLM-S) for expression of HBV large envelope
protein (LHBs), known to have a promiscuous transactivation function
qualitatively and quantitatively similar to that of HBx
(28), was contransfected.
In HepG2 cells, all three promoters tested were stimulated by DHBx
proteins expressed from constructs pDHBV-M1X and -M28X,
but not by the
putative amino-terminally truncated DHBx expressed
from construct
pDHBV-M28X-stop (Fig.
7A, left).
Therefore, the
first 28 amino acids encoded by the X-like ORF are
dispensable
for the transactivation function whereas most of the
remaining
sequences are needed. All three promoters were transactivated
about fivefold by DHBx, which is similar to the value obtained
by the
expression of the control protein LHBs. Similar transactivation
profiles were obtained in 293 cells when the same plasmids were
used
(Fig.
7A, right). These results demonstrate that DHBx is
a promiscuous
transactivator of promoters of cellular and viral
origin which
functions in liver as well as in non-liver-derived
cells.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
Transactivation activity of DHBx analyzed by CAT assay.
(A) Activity of AP1, NF B, and simian virus 40 promoter elements
(3xAP1, 2xNF B, and pSV40) in HepG2 and 293 cells when cotransfected
with plasmids expressing DHBx proteins and LHBs, as determined by CAT
assay. (B) Activity of the promoter containing three AP1 elements by
DHBx proteins and LHBs in HepG2 cells when transdominant-negative
mutants of Raf1 (+ND-Raf) or ERK2 (+ND-ErK2) are coexpressed.
|
|
The transcription activation function of HBx, and also of
LHBs, is mediated by cytoplasmic signaling cascades which lead to
activation of the Raf-MAP kinase pathway (
2,
28,
47). In
order to determine whether the transactivation activity of the
DHBx
protein is also mediated by the Raf-MAP kinase cascade, the
plasmids
expressing the DHBV-M1X and DHBV-M28X proteins were cotransfected
into
HepG2 cells with plasmids expressing dominant-negative mutants
of Raf
and ERK2 (
28). In this assay, the CAT reporter gene was
expressed under the control of a promoter containing the AP1 response
element known to mediate activation of the Raf-MAP pathway. Both
dominant-negative proteins, Raf and ERK2, effectively inhibited
both
the transactivation activity of the control LHBs and that
of the DHBx
proteins (Fig.
7B). Expression of luciferase from
a cotransfected
control plasmid was unaffected, which rules out
the possibility that
the observed inhibition of activation is
due to nonspecific
cytotoxicity or squelching (data not shown).
These data imply that
transactivation of promoters by DHBx depends
on the activation of the
Raf-MAP kinase cascade
pathway.
 |
DISCUSSION |
Although the functions of mammalian hepadnavirus X-proteins have
been studied in great detail in vitro, there is still much debate about
the in vivo relevance of many of these findings. One reason for this is
the lack of a convenient animal system, such as DHBV-infected ducks,
which would allow detailed in vivo studies to be performed. The
presumed lack of an X gene in DHBV has frequently been used as a strong
argument for the association of chronic hepadnavirus infection with the
development of liver carcinoma in mammals but not in ducks. In our
study we challenge this view by demonstrating the existence and
expression of a hidden ORF located at a position analogous to that of
mammalian hepadnavirus X genes. The corresponding protein, DHBx, was
shown to have a transcription-regulatory function and subcellular
localization strikingly similar to those documented for the mammalian
hepadnavirus X-proteins. The data presented indicate that ducks
chronically infected with DHBV provide a convenient animal model to
unravel the still-enigmatic in vivo functions of X proteins and suggest that X genes were present in hepadnavirus genomes early in evolution but diverged in sequence through host adaptation. Our data also suggest
an in vivo function of X proteins in the life cycles of all hepadnaviruses.
Comparison of the primary protein sequences of DHBx and the X
proteins of mammalian hepadnaviruses revealed low similarity when
appropriate artificial deletions for optimal alignment are introduced
(Fig. 8). This may indicate similar
three-dimensional structures of both types of protein even though
secondary-structure predictions are not in strong favor of this
possibility (data not shown). Alternatively, both types of proteins may
have evolved into different structures capable of activating the same
signaling pathways. Consistent with this speculation is a recent report of very similar transactivation mechanisms induced by HBx and the
regulatory protein Tax of human T-cell leukemia virus, which also have
no primary sequence similarity (51).

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 8.
Sequence alignment of HBx, WHx, GHBx, and DHBx proteins.
Identical (dark shaded boxes) and similar (light shaded boxes) amino
acids are indicated. Gaps introduced for optimal alignment by the
ClustalW program of the MacVector software are marked by dashes.
|
|
Our data raise the question as to why DHBx and all other putative
avian X proteins are smaller than their mammalian hepadnavirus counterparts. One possible answer is that avian X proteins have fewer
functions and cellular interaction partners. Alternatively, the avian X
proteins may lack only specific putative co-oncogenic functions
believed to be associated with the X proteins of mammalian hepadnaviruses. For instance, DHBx may lack a domain functionally homologous to the first 50 amino-terminal amino acids of HBx, which are
apparently sufficient for transformation of immortalized cells
(23). Recent evidence suggesting that stop codons
immediately upstream of the DHBx-encoding ORF (42) may
have been lost during evolution supports this speculation. Furthermore,
DHBx, unlike HBx, may not upregulate the expression of the
proinflammatory cytokines, such as tumor necrosis factor
and
interleukin 6 (39, 41), because liver inflammation
believed to contribute to HBV-mediated tumor development is virtually
absent in chronically infected ducks. We consider this less likely
because the transcription-regulatory function of HBx proposed in most
previous reports to play a role in hepatocarcinogenesis appears to be
quantitatively and qualitatively similar in DHBx. In addition, the
minimal sequence length of HBx shown to be required for transcriptional
transactivation and interaction with most cellular proteins (22,
30, 38, 50-52) is similar to that of DHBx.
We have shown predominant cytoplasmic localization of DHBx when
it is overexpressed under the control of a strong foreign promoter, and
most studies of HBx have led to a similar intracellular staining
pattern. However, our studies do not exclude the possibility that a
proportion of DHBx is also in the nucleus but escaped detection due to
its small amount or inaccessibility to our antibodies. The increasing
evidence for the existence of nuclear WHx and HBx and the difficulties
associated with their detection by immunostaining or cell fractionation
(13, 15, 26, 49, 54, 69) are in favor of this possibility.
As there is no obvious nuclear localization sequence in DHBx, it is
conceivable that a fraction of DHBx is transported to the nucleus by a
piggyback mechanism or by passive diffusion and binding to a nuclear
protein, similar to what has been demonstrated or speculated previously
for mammalian X proteins (13, 15, 26, 49, 54, 69). The low
level of DHBx expression in the infected liver is reminiscent of the
difficulties in detecting HBx and WHx in infected livers. It was
estimated that a WHV-infected woodchuck hepatocyte contains only about
1,000 to 10,000 molecules of WHx (14), and this level
probably needs to be kept very low to prevent toxic or proapototic
effects (5, 12, 14).
At present, we can only speculate as to how DHBx is produced.
While splicing events could create RNA molecules with a conventional AUG start codon for DHBx translation, conserved sequences indicative of
intron-exon boundaries are not evident. In contrast to DHBV, all the
other avihepadnaviruses contain an X-like ORF with a conserved AUG
start codon which may serve as the translation initiation codon for the
corresponding proteins. It is conceivable, therefore, that synthesis of
DHBx starts at a position corresponding to a nonconventional start
codon on an unspliced mRNA. The detection of a strong promoter within a
200-bp-long region upstream of the DHBx ORF in LMH cells transfected
with corresponding reporter constructs (preliminary data not shown)
supports this assumption. However, corresponding mRNAs extracted from
DHBV-infected ducks are neither detectable by Northern blotting (Fig.
3E) nor evident in S1 mapping and primer extension studies
(7). It is conceivable that a terminally redundant mRNA
very similar in size to and comigrating with the pregenomic RNA is the
template for DHBx translation. Similar to what has been shown for HBV,
such a DHBx mRNA may be initiated upstream of the DHBx coding region
and processed only at the second transit of the single processing or
poly(A) site, as reported for an HBx mRNA (25).
There are numerous reports describing initiation of translation
at non-AUG codons of both cellular and viral mRNAs (21, 24,
37). Within the DHBx-encoding ORF of DHBV3, there are several
in-frame non-AUG start codons (Fig. 1B) which may be used for
translation initiation. The sizes of DHBx proteins artificially initiated at codon 1 (15 kDa) or 28 (10 kDa) as expressed under foreign
promoter control and those expressed in full-length DHBV DNA-transfected cell lines and in infected livers (12 kDa) would be
compatible with DHBx translation initiation between codons 1 and 28 of
the hidden ORF. Taking this into account, only 3 of 10 potential
alternative translation codons described for eukaryotes and viruses are
potential candidates: codons CUG, UUG, and AUU at positions 8 or 26, 12 or 25, and 24, respectively. Mutagenesis of these codons and the
corresponding adjacent region should provide a clear answer as to
which, if any, of these are used and whether a specific IRES-like
structure of the corresponding mRNA is present and required for correct
initiation of translation of DHBx. Potential translation of DHBx from a
minor undetectable mRNA is an alternative possibility which needs to be
investigated by techniques more sensitive than those currently
available. Furthermore, our data also do not exclude the possibility
that DHBx is synthesized by the processing of a viral fusion protein
which may be produced by ribosomal frameshifting or from a spliced
mRNA, similar to what is known for other viral proteins.
As pointed out in a recent review, it has been very difficult to define
the exact roles of X proteins in vivo because of the necessity of
working with woodchucks (70). DHBV infections in ducks
represent the most convenient animal system and provide unique
opportunities to study the in vivo functions of X proteins in the
hepadnavirus life cycle, establishment of chronic infection, and immune
surveillance. In addition, studies can also be performed with duck
primary hepatocytes derived from embryonated eggs, which are easy to
prepare and permissive for infection. Thus, for instance, the
hepatocyte differentiation-dependent effect of hepadnavirus X protein
reported recently (65) can also be studied without the
necessity for an animal facility. Finally, the availability of viral
genomes from avian hepadnaviruses from different species allows
X-gene-swapping experiments to be performed, which may uncover possible
viral genome- and host-specific differences in avian X-protein
functions, similar to those initiated for ground squirrel hepatitis
virus and WHV (58).
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge the expert technical assistance of
Kerstin Reumann. The critical reading of the manuscript by Thomas Macnaughton and Wolfram Gerlich is very much appreciated.
The Heinrich-Pette-Institut is supported by the Bundesministerium
für Gesundheit, Berlin, and the Freie und Hansestadt Hamburg. Hans Jürgen Netter was supported in part by a grant from the National Health and Medical Research Council of Australia.
 |
FOOTNOTES |
*
Corresponding author. Mailing address:
Heinrich-Pette-Institut, Martinistrasse 52, 20251 Hamburg, Germany.
Phone: 49-40-48051-221. Fax: 49-40-48051-222. E-mail:
will{at}hpi.uni-hamburg.de.
 |
REFERENCES |
| 1.
|
Andrisani, O. M., and S. Barnabas.
1999.
The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis.
Int. J. Oncol.
15:373-379[Medline].
|
| 2.
|
Benn, J., and R. J. Schneider.
1994.
Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade.
Proc. Natl. Acad. Sci. USA
91:10350-10354[Abstract/Free Full Text].
|
| 3.
|
Benn, J., and R. J. Schneider.
1995.
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.
Proc. Natl. Acad. Sci. USA
92:11215-11219[Abstract/Free Full Text].
|
| 4.
|
Benn, J.,
F. Su,
M. Doria, and R. J. Schneider.
1996.
Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases.
J. Virol.
70:4978-4985[Abstract/Free Full Text].
|
| 5.
|
Bergametti, F.,
S. Prigent,
B. Luber,
A. Benoit,
P. Tiollais,
A. Sarasin, and C. Transy.
1999.
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines.
Oncogene
18:2860-2871[CrossRef][Medline].
|
| 6.
|
Blum, H. E.,
Z. S. Zhang,
E. Galun,
F. von Weizsacker,
B. Garner,
T. J. Liang, and J. R. Wands.
1992.
Hepatitis B virus X protein is not central to the viral life cycle in vitro.
J. Virol.
66:1223-1227[Abstract/Free Full Text].
|
| 7.
|
Buscher, M.,
W. Reiser,
H. Will, and H. Schaller.
1985.
Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription.
Cell
40:717-724[CrossRef][Medline].
|
| 8.
|
Caselmann, W. H., and R. Koshy.
1998.
Transactivators of HBV, signal transduction and tumorigenesis, p. 161-181.
In
R. Koshy, and W. H. Caselmann (ed.), Hepatitis B virus: molecular mechanisms in disease and novel strategies for therapy. Imperial College, London, United Kingdom.
|
| 9.
|
Chang, S. F.,
H. J. Netter,
M. Bruns,
R. Schneider,
K. Froeich, and H. Will.
1999.
A new avian hepadnavirus infecting snow geese (Anser caerulescens) produces a significant fraction of virions containing single stranded DNA.
Virology
262:39-54[CrossRef][Medline].
|
| 10.
|
Chen, H. S.,
S. Kaneko,
R. Girones,
R. W. Anderson,
W. E. Hornbuckle,
B. C. Tennant,
P. J. Cote,
J. L. Gerin,
R. H. Purcell, and R. H. Miller.
1993.
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.
J. Virol.
67:1218-1226[Abstract/Free Full Text].
|
| 11.
|
Cheong, J. H.,
M. Yi,
Y. Lin, and S. Murakami.
1995.
Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation.
EMBO J.
14:143-150[Medline].
|
| 12.
|
Chirillo, P.,
S. Pagano,
G. Natoli,
P. L. Puri,
V. L. Burgio,
C. Balsano, and M. Levrero.
1997.
The hepatitis B virus X gene induces p53-mediated programmed cell death.
Proc. Natl. Acad. Sci. USA
94:8162-8167[Abstract/Free Full Text].
|
| 13.
|
Dandri, M.,
J. Petersen,
R. J. Stockert,
T. M. Harris, and C. E. Rogler.
1998.
Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework.
J. Virol.
72:9359-9364[Abstract/Free Full Text].
|
| 14.
|
Dandri, M.,
P. Schirmacher, and C. E. Rogler.
1996.
Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.
J. Virol.
70:5246-5254[Abstract/Free Full Text].
|
| 15.
|
Doria, M.,
N. Klein,
R. Lucito, and R. J. Schneider.
1995.
The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors.
EMBO J.
14:4747-4757[Medline].
|
| 16.
|
Duflot, A.,
R. Mehrotra,
S. Z. Yu,
L. Barraud,
C. Trepo, and L. Cova.
1995.
Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma.
Hepatology
21:1483-1491[CrossRef][Medline].
|
| 17.
|
Elmore, L. W.,
A. R. Hancock,
S. F. Chang,
X. W. Wang,
S. Chang,
C. P. Callahan,
D. A. Geller,
H. Will, and C. C. Harris.
1997.
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis.
Proc. Natl. Acad. Sci. USA
94:14707-14712[Abstract/Free Full Text].
|
| 18.
|
Feitelson, M. A., and R. H. Miller.
1988.
X gene-related sequences in the core gene of duck and heron hepatitis B viruses.
Proc. Natl. Acad. Sci. USA
85:6162-6166[Abstract/Free Full Text].
|
| 19.
|
Fischer, M.,
L. Runkel, and H. Schaller.
1995.
HBx protein of hepatitis B virus interacts with the C-terminal portion of a novel human proteasome alpha-subunit.
Virus Genes
10:99-102[CrossRef][Medline].
|
| 20.
|
Ganem, D.
1996.
Hepadnaviridae and their replication, p. 2703-2737.
In
Fields et al. (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 21.
|
Gordon, K.,
J. Futterer, and T. Hohn.
1992.
Efficient initiation of translation at non-AUG triplets in plant cells.
Plant J.
2:809-813[CrossRef][Medline].
|
| 22.
|
Gottlob, K.,
M. Fulco,
M. Levrero, and A. Graessmann.
1998.
The hepatitis B virus HBx protein inhibits caspase 3 activity.
J. Biol. Chem.
273:33347-33353[Abstract/Free Full Text].
|
| 23.
|
Gottlob, K.,
S. Pagano,
M. Levrero, and A. Graessmann.
1998.
Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation.
Cancer Res.
58:3566-3570[Abstract/Free Full Text].
|
| 24.
|
Gray, N. K., and M. Wickens.
1998.
Control of translation initiation in animals.
Annu. Rev. Cell Dev. Biol.
14:399-458[CrossRef][Medline].
|
| 25.
|
Guo, W. T.,
J. Wang,
G. Tam,
T. S. Yen, and J. S. Ou.
1991.
Leaky transcription termination produces larger and smaller than genome size hepatitis B virus X gene transcripts.
Virology
181:630-636[CrossRef][Medline].
|
| 26.
|
Haviv, I.,
M. Shamay,
G. Doitsh, and Y. Shaul.
1998.
Hepatitis B virus pX targets TFIIB in transcription coactivation.
Mol. Cell. Biol.
18:1562-1569[Abstract/Free Full Text].
|
| 27.
|
Haviv, I.,
D. Vaizel, and Y. Shaul.
1996.
pX, the HBV-encoded coactivator, interacts with components of the transcription machinery and stimulates transcription in a TAF-independent manner.
EMBO J.
15:3413-3420[Medline].
|
| 28.
|
Hildt, E.,
G. Saher,
V. Bruss, and P. H. Hofschneider.
1996.
The hepatitis B virus large surface protein (LHBs) is a transcriptional activator.
Virology
225:235-239[CrossRef][Medline].
|
| 29.
|
Hohne, M.,
S. Schaefer,
M. Seifer,
M. A. Feitelson,
D. Paul, and W. H. Gerlich.
1990.
Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA.
EMBO J.
9:1137-1145[Medline].
|
| 30.
|
Hu, Z.,
Z. Zhang,
E. Doo,
O. Coux,
A. L. Goldberg, and T. J. Liang.
1999.
Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex.
J. Virol.
73:7231-7240[Abstract/Free Full Text].
|
| 31.
|
Huang, J.,
J. Kwong,
E. C. Sun, and T. J. Liang.
1996.
Proteasome complex as a potential cellular target of hepatitis B virus X protein.
J. Virol.
70:5582-5591[Abstract/Free Full Text].
|
| 32.
|
Jacob, J. R.,
M. A. Ascenzi,
C. A. Roneker,
I. A. Toshkov,
P. J. Cote,
J. L. Gerin, and B. C. Tennant.
1997.
Hepatic expression of the woodchuck hepatitis virus X-antigen during acute and chronic infection and detection of a woodchuck hepatitis virus X-antigen antibody response.
Hepatology
26:1607-1615[CrossRef][Medline].
|
| 33.
|
Jia, L.,
X. W. Wang, and C. C. Harris.
1999.
Hepatitis B virus X protein inhibits nucleotide excision repair.
Int. J. Cancer
80:875-879[CrossRef][Medline].
|
| 34.
|
Kekule, A. S.,
U. Lauer,
L. Weiss,
B. Luber, and P. H. Hofschneider.
1993.
Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway.
Nature
361:742-745[CrossRef][Medline].
|
| 35.
|
Kim, C. M.,
K. Koike,
I. Saito,
T. Miyamura, and G. Jay.
1991.
HBx gene of hepatitis B virus induces liver cancer in transgenic mice.
Nature
351:317-320[CrossRef][Medline].
|
| 36.
|
Kolch, W.,
G. Heidecker,
G. Kochs,
R. Hummel,
H. Vahidi,
H. Mischak,
G. Finkenzeller,
D. Marme, and U. R. Rapp.
1993.
Protein kinase C alpha activates RAF-1 by direct phosphorylation.
Nature
364:249-252[CrossRef][Medline].
|
| 37.
|
Kozak, M.
1999.
Initiation of translation in prokaryotes and eukaryotes.
Gene
234:187-208[CrossRef][Medline].
|
| 38.
|
Kumar, V.,
N. Jayasuryan, and R. Kumar.
1996.
A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function.
Proc. Natl. Acad. Sci. USA
93:5647-5652[Abstract/Free Full Text].
|
| 39.
|
Lara, P. E.,
P. L. Majano,
G. M. Gomez,
M. C. Garcia,
O. R. Moreno,
M. Levrero, and C. M. Lopez.
1998.
The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes.
Hepatology
28:1013-1021[CrossRef][Medline].
|
| 40.
|
Lee, T. H.,
S. J. Elledge, and J. S. Butel.
1995.
Hepatitis B virus X protein interacts with a probable cellular DNA repair protein.
J. Virol.
69:1107-1114[Abstract].
|
| 41.
|
Lee, Y.,
U. S. Park,
I. Choi,
S. K. Yoon,
Y. M. Park, and Y. I. Lee.
1998.
Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells.
Clin. Cancer Res.
4:1711-1717[Abstract].
|
| 42.
|
Lin, B., and D. A. Anderson.
2000.
A vestigial X open reading frame in duck hepatitis B virus.
Intervirology
43:185-190[CrossRef][Medline].
|
| 43.
|
Liu, C.,
L. D. Condreay,
J. B. Burch, and W. Mason.
1991.
Characterization of the core promoter and enhancer of duck hepatitis B virus.
Virology
184:242-252[CrossRef][Medline].
|
| 44.
|
Maguire, H. F.,
J. P. Hoeffler, and A. Siddiqui.
1991.
HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions.
Science
252:842-844[Abstract/Free Full Text].
|
| 45.
|
Melegari, M.,
P. P. Scaglioni, and J. R. Wands.
1998.
Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication.
J. Virol.
72:1737-1743[Abstract/Free Full Text].
|
| 46.
|
Murakami, S.
1999.
Hepatitis B virus X protein: structure, function and biology.
Intervirology
42:81-99[CrossRef][Medline].
|
| 47.
|
Natoli, G.,
M. L. Avantaggiati,
P. Chirillo,
P. L. Puri,
A. Ianni,
C. Balsano, and M. Levrero.
1994.
Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX.
Oncogene
9:2837-2843[Medline].
|
| 48.
|
Netter, H. J.,
S. Chassot,
S. F. Chang,
L. Cova, and H. Will.
1997.
Sequence heterogeneity of heron hepatitis B virus genomes determined by full-length DNA amplification and direct sequencing reveals novel and unique features.
J. Gen. Virol.
78:1707-1718[Abstract].
|
| 49.
|
Nomura, T.,
Y. Lin,
D. Dorjsuren,
S. Ohno,
T. Yamashita, and S. Murakami.
1999.
Human hepatitis B virus X protein is detectable in nuclei of transfected cells, and is active for transactivation.
Biochim. Biophys. Acta
1453:330-340[Medline].
|
| 50.
|
Ohno, H.,
S. Kaneko,
Y. Lin,
K. Kobayashi, and S. Murakami.
1999.
Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain.
J. Med. Virol.
58:11-18[CrossRef][Medline].
|
| 51.
|
Perini, G.,
E. Oetjen, and M. R. Green.
1999.
The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region/leucine zipper proteins by targeting the conserved basic region.
J. Biol. Chem.
274:13970-13977[Abstract/Free Full Text].
|
| 52.
|
Runkel, L.,
M. Fischer, and H. Schaller.
1993.
Two-codon insertion mutations of the HBx define two separate regions necessary for its trans-activation function.
Virology
197:529-536[CrossRef][Medline].
|
| 53.
|
Schaefer, S.,
T. Tolle,
S. Lottmann, and W. H. Gerlich.
1998.
Animal models and experimental systems in hepatitis B virus research, p. 51-74.
In
R. Koshy, and W. H. Caselmann (ed.), Hepatitis B virus: molecular mechanisms in disease and novel strategies for therapy. Imperial College Press, London, United Kingdom.
|
| 54.
|
Schek, N.,
R. Bartenschlager,
C. Kuhn, and H. Schaller.
1991.
Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccinia virus.
Oncogene
6:1735-1744[Medline].
|
| 55.
|
Schneider, R., and H. Will.
1991.
Regulatory sequences of duck hepatitis B virus C gene transcription.
J. Virol.
65:5693-5701[Abstract/Free Full Text].
|
| 56.
|
Schuster, R.,
W. H. Gerlich, and S. Schaefer.
2000.
Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts.
Oncogene
19:1173-1180[CrossRef][Medline].
|
| 57.
|
Seeger, C.
1997.
The hepatitis B virus X protein: the quest for a role in viral replication and pathogenesis.
Hepatology
25:496-498[CrossRef][Medline].
|
| 58.
|
Seeger, C.,
B. Baldwin,
W. E. Hornbuckle,
A. E. Yeager,
B. C. Tennant,
P. Cote,
L. Ferrell,
D. Ganem, and H. E. Varmus.
1991.
Woodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host.
J. Virol.
65:1673-1679[Abstract/Free Full Text].
|
| 59.
|
Seifer, M.,
M. Hohne,
S. Schaefer, and W. H. Gerlich.
1991.
In vitro tumorigenicity of hepatitis B virus DNA and HBx protein.
J. Hepatol.
13(Suppl. 4):S61-S65.
|
| 60.
|
Shin, E. C.,
J. S. Shin,
J. H. Park,
H. Kim, and S. J. Kim.
1999.
Expression of fas ligand in human hepatoma cell lines: role of hepatitis-B virus X (HBX) in induction of Fas ligand.
Int. J. Cancer
82:587-591[CrossRef][Medline].
|
| 61.
|
Shirakata, Y.,
M. Kawada,
Y. Fujiki,
H. Sano,
M. Oda,
K. Yaginuma,
M. Kobayashi, and K. Koike.
1989.
The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells.
Jpn. J. Cancer Res.
80:617-621[CrossRef][Medline].
|
| 62.
|
Slagle, B. L.,
T. H. Lee,
D. Medina,
M. J. Finegold, and J. S. Butel.
1996.
Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene.
Mol. Carcinog.
15:261-269[CrossRef][Medline].
|
| 63.
|
Sprengel, R.,
R. Schneider,
P. L. Marion,
D. Fernholz,
G. Wildner, and H. Will.
1991.
Comparative sequence analysis of defective and infectious avian hepadnaviruses.
Nucleic Acids Res
19:4289[Free Full Text].
|
| 64.
|
Su, Q.,
C. H. Schroder,
W. J. Hofmann,
G. Otto,
R. Pichlmayr, and P. Bannasch.
1998.
Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas.
Hepatology
27:1109-1120[CrossRef][Medline].
|
| 65.
|
Tarn, C.,
M. L. Bilodeau,
R. L. Hullinger, and O. M. Andrisani.
1999.
Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines.
J. Biol. Chem.
274:2327-2336[Abstract/Free Full Text].
|
| 66.
|
Terradillos, O.,
T. Pollicino,
H. Lecoeur,
M. Tripodi,
M. L. Gougeon,
P. Tiollais, and M. A. Buendia.
1998.
p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro.
Oncogene
17:2115-2123[CrossRef][Medline].
|
| 67.
|
Wang, X. W.,
M. K. Gibson,
W. Vermeulen,
H. Yeh,
K. Forrester,
H. W. Sturzbecher,
J. H. Hoeijmakers, and C. C. Harris.
1995.
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene.
Cancer Res.
55:6012-6016[Abstract/Free Full Text].
|
| 68.
|
Warren, K. S.,
J. L. Heeney,
R. A. Swan,
Heriyanto, and E. J. Verschoor.
1999.
A new group of hepadnaviruses naturally infecting orangutans (Pongo pygmaeus).
J. Virol.
73:7860-7865[Abstract/Free Full Text].
|
| 69.
|
Weil, R.,
H. Sirma,
C. Giannini,
D. Kremsdorf,
C. Bessia,
C. Dargemont,
C. Brechot, and A. Israel.
1999.
Direct association and nuclear import of the hepatitis B virus X protein with the NF B inhibitor I B .
Mol. Cell. Biol.
19:6345-6354[Abstract/Free Full Text].
|
| 70.
|
Yen, T. S. B.
1996.
Hepadnaviral X protein: review of recent progress.
J. Biomed. Sci.
3:20-30[CrossRef][Medline].
|
| 71.
|
Yu, D. Y.,
H. B. Moon,
J. K. Son,
S. Jeong,
S. L. Yu,
H. Yoon,
Y. M. Han,
C. S. Lee,
J. S. Park,
C. H. Lee,
B. H. Hyun,
S. Murakami, and K. K. Lee.
1999.
Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein.
J. Hepatol.
31:123-132[CrossRef][Medline].
|
| 72.
|
Zoulim, F.,
J. Saputelli, and C. Seeger.
1994.
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
J. Virol.
68:2026-2030[Abstract/Free Full Text].
|
Journal of Virology, January 2001, p. 161-170, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.161-170.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Cao, F., Scougall, C. A., Jilbert, A. R., Tavis, J. E.
(2009). Pre-P Is a Secreted Glycoprotein Encoded as an N-Terminal Extension of the Duck Hepatitis B Virus Polymerase Gene. J. Virol.
83: 1368-1378
[Abstract]
[Full Text]
-
Clippinger, A. J., Bouchard, M. J.
(2008). Hepatitis B Virus HBx Protein Localizes to Mitochondria in Primary Rat Hepatocytes and Modulates Mitochondrial Membrane Potential. J. Virol.
82: 6798-6811
[Abstract]
[Full Text]
-
Bouchard, M. J., Wang, L., Schneider, R. J.
(2006). Activation of Focal Adhesion Kinase by Hepatitis B Virus HBx Protein: Multiple Functions in Viral Replication. J. Virol.
80: 4406-4414
[Abstract]
[Full Text]
-
Guo, H., Mason, W. S., Aldrich, C. E., Saputelli, J. R., Miller, D. S., Jilbert, A. R., Newbold, J. E.
(2005). Identification and Characterization of Avihepadnaviruses Isolated from Exotic Anseriformes Maintained in Captivity. J. Virol.
79: 2729-2742
[Abstract]
[Full Text]
-
Bouchard, M. J., Schneider, R. J.
(2004). The Enigmatic X Gene of Hepatitis B Virus. J. Virol.
78: 12725-12734
[Full Text]
-
Prassolov, A., Hohenberg, H., Kalinina, T., Schneider, C., Cova, L., Krone, O., Frolich, K., Will, H., Sirma, H.
(2003). New Hepatitis B Virus of Cranes That Has an Unexpected Broad Host Range. J. Virol.
77: 1964-1976
[Abstract]
[Full Text]
-
Kidd-Ljunggren, K., Miyakawa, Y., Kidd, A. H.
(2002). Genetic variability in hepatitis B viruses. J. Gen. Virol.
83: 1267-1280
[Abstract]
[Full Text]
-
Rinninger, F., Brundert, M., Brosch, I., Donarski, N., Budzinski, R. M., Greten, H.
(2001). Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI. J. Lipid Res.
42: 1740-1751
[Abstract]
[Full Text]